|
US6291425B1
(en)
*
|
1999-09-01 |
2001-09-18 |
Guilford Pharmaceuticals Inc. |
Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
|
|
US7517880B2
(en)
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
|
US7329670B1
(en)
|
1997-12-22 |
2008-02-12 |
Bayer Pharmaceuticals Corporation |
Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
|
|
PT1140840E
(pt)
*
|
1999-01-13 |
2006-05-31 |
Bayer Pharmaceuticals Corp |
Difenilureias substituidas com (.)-carboxiarilo como inibidores de raf-quinase
|
|
US7928239B2
(en)
*
|
1999-01-13 |
2011-04-19 |
Bayer Healthcare Llc |
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
CA2549558C
(en)
*
|
1999-01-13 |
2010-08-31 |
Bayer Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP1158985B1
(en)
*
|
1999-01-13 |
2011-12-28 |
Bayer HealthCare LLC |
OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
|
|
ME00275B
(me)
|
1999-01-13 |
2011-02-10 |
Bayer Corp |
ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
|
|
EP1140840B1
(en)
*
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
AU1529901A
(en)
|
1999-11-22 |
2001-06-04 |
Smithkline Beecham Plc |
Compounds
|
|
ATE266022T1
(de)
|
2000-03-06 |
2004-05-15 |
Smithkline Beecham Plc |
Imidazol derivate als raf kinase inhibitoren
|
|
GB0005357D0
(en)
|
2000-03-06 |
2000-04-26 |
Smithkline Beecham Plc |
Compounds
|
|
US6645990B2
(en)
|
2000-08-15 |
2003-11-11 |
Amgen Inc. |
Thiazolyl urea compounds and methods of uses
|
|
AU9598601A
(en)
|
2000-10-20 |
2002-04-29 |
Eisai Co Ltd |
Nitrogenous aromatic ring compounds
|
|
JP2004517080A
(ja)
|
2000-11-29 |
2004-06-10 |
グラクソ グループ リミテッド |
Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
UA76977C2
(en)
|
2001-03-02 |
2006-10-16 |
Icos Corp |
Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
|
|
AU2002306618B2
(en)
*
|
2001-03-07 |
2006-11-09 |
Telik, Inc. |
Substituted diarylureas as stimulators for Fas-mediated apoptosis
|
|
US7371763B2
(en)
|
2001-04-20 |
2008-05-13 |
Bayer Pharmaceuticals Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
EP1379505B1
(en)
*
|
2001-04-20 |
2007-02-28 |
Bayer Pharmaceuticals Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
GB0112348D0
(en)
|
2001-05-19 |
2001-07-11 |
Smithkline Beecham Plc |
Compounds
|
|
AU2002317377A1
(en)
*
|
2001-07-20 |
2003-03-03 |
Cancer Research Technology Limited |
Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
|
|
US10653684B2
(en)
|
2002-02-11 |
2020-05-19 |
Bayer Healthcare Llc |
Aryl ureas with angiogenisis inhibiting activity
|
|
WO2003068229A1
(en)
*
|
2002-02-11 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
|
|
ATE529406T1
(de)
*
|
2002-02-11 |
2011-11-15 |
Bayer Healthcare Llc |
Aryl-harnstoffe als kinase inhibitoren
|
|
SI1478358T1
(sl)
|
2002-02-11 |
2013-09-30 |
Bayer Healthcare Llc |
Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
|
|
PE20040522A1
(es)
|
2002-05-29 |
2004-09-28 |
Novartis Ag |
Derivados de diarilurea dependientes de la cinasa de proteina
|
|
ATE372770T1
(de)
*
|
2002-08-01 |
2007-09-15 |
Neurosearch As |
Verbindungen nützlich in der behandlung von erkrankungen die auf anti-angiogenertherapie antworten
|
|
US20040034038A1
(en)
*
|
2002-08-13 |
2004-02-19 |
Goaquan Li |
Urea kinase inhibitors
|
|
US7056925B2
(en)
|
2002-08-13 |
2006-06-06 |
Abbott Laboratories |
Urea kinase inhibitors
|
|
ATE552236T1
(de)
|
2003-01-14 |
2012-04-15 |
Cytokinetics Inc |
Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz
|
|
WO2004078748A2
(en)
|
2003-02-28 |
2004-09-16 |
Bayer Pharmaceuticals Corporation |
Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
|
|
MXPA05009102A
(es)
*
|
2003-02-28 |
2006-05-31 |
Bayer Pharmaceuticals Corp |
Derivados de piridina sustituida utiles en el tratamiento del cancer y otros trastornos.
|
|
CA2526285A1
(en)
|
2003-05-15 |
2004-12-23 |
Arqule, Inc. |
Inhibitors of p38 and methods of using the same
|
|
EP1636585B2
(en)
|
2003-05-20 |
2012-06-13 |
Bayer HealthCare LLC |
Diaryl ureas with kinase inhibiting activity
|
|
DE602004000260T2
(de)
|
2003-07-22 |
2006-08-24 |
Arena Pharmaceuticals, Inc., San Diego |
Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
|
|
EP1663978B1
(en)
|
2003-07-23 |
2007-11-28 |
Bayer Pharmaceuticals Corporation |
Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
|
DE10334663A1
(de)
*
|
2003-07-30 |
2005-03-10 |
Merck Patent Gmbh |
Harnstoffderivate
|
|
US7683172B2
(en)
|
2003-11-11 |
2010-03-23 |
Eisai R&D Management Co., Ltd. |
Urea derivative and process for preparing the same
|
|
BRPI0507198A
(pt)
*
|
2004-01-30 |
2007-06-26 |
Merck Patent Gmbh |
derivados de bisariluréia
|
|
TW200530236A
(en)
|
2004-02-23 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Heteroaryl phenylurea
|
|
ATE548353T1
(de)
|
2004-03-23 |
2012-03-15 |
Arena Pharm Inc |
Verfahren zur herstellung von substituierte n- aryl-n'-ä3-(1h-pyrazol-5-yl)phenylü-harnstoffe and intermediate davon.
|
|
EP2295426A1
(en)
|
2004-04-30 |
2011-03-16 |
Bayer HealthCare, LLC |
Substituted pyrazolyl urea derivatives useful in the treatment of cancer
|
|
ES2522579T3
(es)
|
2004-06-17 |
2014-11-17 |
Cytokinetics, Inc. |
Compuestos, composiciones y métodos
|
|
LT2502911T
(lt)
|
2004-06-24 |
2017-09-11 |
Vertex Pharmaceuticals Incorporated |
Atp surišančios kasetės transporterių moduliatoriai
|
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
|
MX2007000265A
(es)
*
|
2004-07-02 |
2007-07-20 |
Icos Corp |
Compuestos utiles para inhibir chk1.
|
|
WO2006010082A1
(en)
|
2004-07-08 |
2006-01-26 |
Arqule, Inc. |
1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
|
|
EP1778648A2
(en)
*
|
2004-08-19 |
2007-05-02 |
ICOS Corporation |
Compounds useful for inhibiting chk1
|
|
MY191349A
(en)
*
|
2004-08-27 |
2022-06-17 |
Bayer Pharmaceuticals Corp |
New pharmaceutical compositions for the treatment of hyper-proliferative disorders
|
|
ATE428421T1
(de)
|
2004-09-17 |
2009-05-15 |
Eisai R&D Man Co Ltd |
Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
|
|
WO2006040056A1
(en)
*
|
2004-10-13 |
2006-04-20 |
Merck Patent Gmbh |
Heterocyclic substituted bisarylurea derivatives as kinase inhibitors
|
|
EP2258704A1
(en)
|
2004-10-19 |
2010-12-08 |
ArQule, Inc. |
Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
|
|
SA05260357B1
(ar)
|
2004-11-19 |
2008-09-08 |
ارينا فارماسيتو تيكالز ، أنك |
مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
|
|
EP1858879B1
(en)
*
|
2005-01-14 |
2012-06-06 |
Gilead Connecticut, Inc. |
1,3-diaryl substituted ureas as modulators of kinase activity
|
|
EP1858877B1
(en)
|
2005-01-14 |
2014-03-12 |
Gilead Connecticut, Inc. |
1,3 substituted diaryl ureas as modulators of kinase activity
|
|
ATE482693T1
(de)
|
2005-03-07 |
2010-10-15 |
Bayer Schering Pharma Ag |
Pharmazeutische zusammensetzung mit einem omega- carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
|
|
WO2007024294A2
(en)
|
2005-05-03 |
2007-03-01 |
Cgi Pharmaceuticals, Inc. |
Certain substituted ureas, as modulators of kinase activity
|
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
|
US7538223B2
(en)
|
2005-08-04 |
2009-05-26 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
|
JP5072595B2
(ja)
|
2005-08-05 |
2012-11-14 |
中外製薬株式会社 |
マルチキナーゼ阻害剤
|
|
US7825120B2
(en)
|
2005-12-15 |
2010-11-02 |
Cytokinetics, Inc. |
Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
|
|
ES2419007T3
(es)
|
2005-12-15 |
2013-08-19 |
Cytokinetics, Inc. |
Ciertas entidades químicas, composiciones y procedimientos
|
|
WO2007078815A2
(en)
|
2005-12-16 |
2007-07-12 |
Cytokinetics, Inc. |
Certain chemical entities, compositions, and methods
|
|
WO2007078839A2
(en)
|
2005-12-19 |
2007-07-12 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
|
WO2007079139A2
(en)
|
2005-12-28 |
2007-07-12 |
Vertex Pharmaceuticals, Inc. |
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
CA2646076C
(en)
|
2006-05-18 |
2015-06-30 |
Arena Pharmaceuticals, Inc. |
Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
|
|
JP5406018B2
(ja)
|
2006-05-18 |
2014-02-05 |
アリーナ ファーマシューティカルズ， インコーポレイテッド |
５−ｈｔ２ａセロトニンレセプターに関連する障害の処置に有用な５−ｈｔ２ａセロトニンレセプターのモジュレーターとしての１級アミン、およびその誘導体
|
|
SG171681A1
(en)
|
2006-05-18 |
2011-06-29 |
Arena Pharm Inc |
Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor
|
|
CN104706637A
(zh)
|
2006-05-18 |
2015-06-17 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
|
EP2094268A2
(en)
|
2006-05-26 |
2009-09-02 |
Bayer HealthCare, LLC |
Drug combinations with substituted diaryl ureas for the treatment of cancer
|
|
WO2008026748A1
(en)
|
2006-08-28 |
2008-03-06 |
Eisai R & D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
|
TWI415845B
(zh)
|
2006-10-03 |
2013-11-21 |
Arena Pharm Inc |
用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
|
|
WO2008044688A1
(en)
*
|
2006-10-11 |
2008-04-17 |
Daiichi Sankyo Company, Limited |
Urea derivative
|
|
JP2010514692A
(ja)
|
2006-12-20 |
2010-05-06 |
バイエル ヘルスケア リミティド ライアビリティ カンパニー |
癌の治療に有用なヒドロキシメチルフェニルピラゾリル尿素化合物
|
|
CA2676796C
(en)
|
2007-01-29 |
2016-02-23 |
Eisai R & D Management Co., Ltd. |
Composition for treatment of undifferentiated gastric cancer
|
|
CN101674833A
(zh)
*
|
2007-03-20 |
2010-03-17 |
柯瑞斯公司 |
含有锌结合半族的Raf激酶抑制剂
|
|
JP5393677B2
(ja)
|
2007-08-15 |
2014-01-22 |
アリーナ ファーマシューティカルズ， インコーポレイテッド |
５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体
|
|
WO2009035949A2
(en)
*
|
2007-09-13 |
2009-03-19 |
Arete Therapeutics, Inc. |
Soluble epoxide hydrolase inhibitors
|
|
US8952035B2
(en)
|
2007-11-09 |
2015-02-10 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
|
NZ586418A
(en)
*
|
2007-12-19 |
2012-09-28 |
Cancer Rec Tech Ltd |
Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
|
|
JP2011513331A
(ja)
|
2008-02-29 |
2011-04-28 |
アレイ バイオファーマ、インコーポレイテッド |
ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤
|
|
KR20100122505A
(ko)
|
2008-02-29 |
2010-11-22 |
어레이 바이오파마 인크. |
Ｒａｆ 저해물질 화합물 및 이들의 이용 방법
|
|
CN101372475B
(zh)
*
|
2008-03-19 |
2012-01-04 |
南京工业大学 |
芳杂环取代的二苯脲类衍生物及其用途
|
|
US20110021538A1
(en)
|
2008-04-02 |
2011-01-27 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
|
US12458635B2
(en)
|
2008-08-13 |
2025-11-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
|
US9126946B2
(en)
|
2008-10-28 |
2015-09-08 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
|
|
CA2741731A1
(en)
|
2008-10-28 |
2010-06-03 |
Arena Pharmaceuticals, Inc. |
Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
|
|
SI2408750T1
(sl)
|
2009-03-20 |
2015-11-30 |
Vertex Pharmaceuticals Incorporated |
Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
|
|
MY162940A
(en)
|
2009-08-19 |
2017-07-31 |
Eisai R&D Man Co Ltd |
Quinoline derivative-containing pharmaceutical composition
|
|
JP2013503170A
(ja)
*
|
2009-08-28 |
2013-01-31 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
化合物および方法
|
|
WO2011075596A1
(en)
|
2009-12-18 |
2011-06-23 |
Arena Pharmaceuticals, Inc. |
Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
|
|
CN102958523B
(zh)
|
2010-06-25 |
2014-11-19 |
卫材R&D管理有限公司 |
使用具有激酶抑制作用的组合的抗肿瘤剂
|
|
CA2805874A1
(en)
|
2010-07-19 |
2012-01-26 |
Bayer Healthcare Llc |
Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
|
US8802700B2
(en)
|
2010-12-10 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
CN102134207B
(zh)
*
|
2011-01-14 |
2013-04-17 |
厦门大学 |
一种脲化合物及其制备方法和用途
|
|
CN103402519B
(zh)
|
2011-04-18 |
2015-11-25 |
卫材R&D管理有限公司 |
肿瘤治疗剂
|
|
JP6038128B2
(ja)
|
2011-06-03 |
2016-12-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
|
|
MX353205B
(es)
*
|
2011-08-03 |
2018-01-08 |
Univ Nat Taiwan |
Agonistas de proteína-tirosina-fosfatasa-1 que contiene homología src-2 y métodos de tratamiento que usan los mismos.
|
|
EP2819670A1
(en)
|
2012-02-27 |
2015-01-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administration thereof
|
|
KR20150098605A
(ko)
|
2012-12-21 |
2015-08-28 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
퀴놀린 유도체의 비정질 형태 및 그의 제조방법
|
|
NZ714049A
(en)
|
2013-05-14 |
2020-05-29 |
Eisai R&D Man Co Ltd |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
|
WO2015041534A1
(en)
|
2013-09-20 |
2015-03-26 |
Stichting Het Nederlands Kanker Instituut |
P90rsk in combination with raf/erk/mek
|
|
US9629851B2
(en)
|
2013-09-20 |
2017-04-25 |
Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis |
ROCK in combination with MAPK pathway
|
|
WO2015156674A2
(en)
|
2014-04-10 |
2015-10-15 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
|
WO2015178770A1
(en)
|
2014-05-19 |
2015-11-26 |
Stichting Het Nederlands Kanker Instituut |
Compositions for cancer treatment
|
|
JP6759514B2
(ja)
|
2014-08-01 |
2020-09-23 |
ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ |
ブロモドメインに対して活性な化合物
|
|
PT3524595T
(pt)
|
2014-08-28 |
2022-09-19 |
Eisai R&D Man Co Ltd |
Derivado de quinolina altamente puro e método para produção do mesmo
|
|
KR20170063954A
(ko)
|
2014-10-07 |
2017-06-08 |
버텍스 파마슈티칼스 인코포레이티드 |
낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
|
|
US9638690B2
(en)
|
2014-11-07 |
2017-05-02 |
The University Of British Columbia |
Compounds and compositions for use as alkylating agent sensors and methods of use thereof
|
|
LT3263106T
(lt)
|
2015-02-25 |
2024-01-10 |
Eisai R&D Management Co., Ltd. |
Chinolino darinių kartumo sumažinimo būdas
|
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
|
CN104817493A
(zh)
*
|
2015-03-11 |
2015-08-05 |
西安交通大学 |
一种芳杂环酰胺取代的二芳基脲化合物及其制备方法和应用
|
|
CN104744350A
(zh)
*
|
2015-03-11 |
2015-07-01 |
西安交通大学 |
一种吡啶取代的二芳基脲化合物及其制备方法和应用
|
|
US10022355B2
(en)
|
2015-06-12 |
2018-07-17 |
Axovant Sciences Gmbh |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
|
|
MX373231B
(es)
|
2015-06-16 |
2020-05-08 |
Eisai R&D Man Co Ltd |
Agente anticancerigeno.
|
|
BR112018000728A2
(pt)
|
2015-07-15 |
2018-09-04 |
Axovant Sciences Gmbh |
resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
|
|
CN107922375B
(zh)
*
|
2015-07-30 |
2020-05-22 |
正大天晴药业集团股份有限公司 |
靶向idh2突变的抗肿瘤化合物及其使用方法
|
|
US12220398B2
(en)
|
2015-08-20 |
2025-02-11 |
Eisai R&D Management Co., Ltd. |
Tumor therapeutic agent
|
|
US12303505B2
(en)
|
2017-02-08 |
2025-05-20 |
Eisai R&D Management Co., Ltd. |
Tumor-treating pharmaceutical composition
|
|
RU2019134940A
(ru)
|
2017-05-16 |
2021-06-16 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Лечение гепатоцеллюлярной карциномы
|
|
CN108997209B
(zh)
*
|
2018-06-11 |
2020-08-04 |
山东罗欣药业集团恒欣药业有限公司 |
一种瑞戈非尼的制备方法
|
|
WO2019243523A1
(en)
*
|
2018-06-21 |
2019-12-26 |
Cellestia Biotech Ag |
Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts
|
|
CN110128299B
(zh)
*
|
2019-05-13 |
2020-11-10 |
浙江大学 |
一种二苯基脲类抗肿瘤小分子抑制剂及其制备方法
|
|
CN113121484A
(zh)
|
2019-12-31 |
2021-07-16 |
复星弘创(苏州)医药科技有限公司 |
一种制备3-位被酰胺基烷基取代的香豆素类化合物的方法及其产物和相关中间体
|
|
KR102770474B1
(ko)
*
|
2021-03-23 |
2025-02-21 |
한국과학기술연구원 |
신규한 화합물 및 이를 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물
|